US President Donald Trump has announced a sweeping 100 per cent tariff on imports of branded and patented pharmaceutical products, effective October 1. This move, part of his broader ‘America First’ trade agenda, aims to bolster United States’ domestic drug manufacturing by penalising foreign imports.

In his announcement on Truth Social, Trump wrote, “Starting October 1, 2025, we will be imposing a 100 per cent tariff on any branded or patented pharmaceutical product, unless a company is building their pharmaceutical manufacturing plant in America.”

“There will, therefore, be no tariff on these pharmaceutical products if construction has started,” he added.

In April, the Trump administration launched a Section 232 investigation into pharmaceutical imports. This law allows the US to exam

See Full Page